Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.

Bajgiran AM, Mirak SA, Sung K, Sisk AE, Reiter RE, Raman SS.

AJR Am J Roentgenol. 2019 Jun 19:1-9. doi: 10.2214/AJR.19.21365. [Epub ahead of print]

PMID:
31216201
2.

[89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model.

Zettlitz KA, Tsai WK, Knowles SM, Salazar FB, Kobayashi N, Reiter RE, Wu AM.

Mol Imaging Biol. 2019 Jun 17. doi: 10.1007/s11307-019-01386-7. [Epub ahead of print]

PMID:
31209779
3.

Focal Therapy Should Not Be Considered for Men with Gleason Grade Group 3-5 Prostate Cancer.

Johnson DC, Reiter RE.

Eur Urol Focus. 2019 Jun 12. pii: S2405-4569(19)30160-9. doi: 10.1016/j.euf.2019.06.005. [Epub ahead of print]

PMID:
31202786
4.

First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.

Kang JJ, Reiter RE, Steinberg ML, King CR.

Eur Urol Oncol. 2018 Oct;1(5):378-385. doi: 10.1016/j.euo.2018.07.008. Epub 2018 Aug 22.

PMID:
31158076
5.

The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17.

PMID:
31099673
6.

Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.

Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter RE.

Cancer. 2019 May 1. doi: 10.1002/cncr.32170. [Epub ahead of print]

PMID:
31042322
7.

Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation.

Wibulpolprasert P, Raman SS, Hsu W, Margolis DJA, Asvadi NH, Khoshnoodi P, Moshksar A, Tan N, Ahuja P, Maehara CK, Huang J, Sayre J, Lu DSK, Reiter RE.

AJR Am J Roentgenol. 2019 Apr 17:W1-W10. doi: 10.2214/AJR.18.20113. [Epub ahead of print]

PMID:
30995090
8.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208-8. doi: 10.1016/j.eururo.2019.03.022. [Epub ahead of print]

PMID:
30992160
9.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

10.

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team.

Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206-4. doi: 10.1016/j.eururo.2019.03.020. [Epub ahead of print]

PMID:
30928160
11.

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.

JAMA Oncol. 2019 Mar 28. doi: 10.1001/jamaoncol.2019.0096. [Epub ahead of print]

12.

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.

Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ.

Mol Cancer Res. 2019 Jun;17(6):1235-1240. doi: 10.1158/1541-7786.MCR-18-1101. Epub 2019 Mar 27.

PMID:
30918106
13.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
14.

Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT.

Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J.

Clin Nucl Med. 2019 May;44(5):e353-e356. doi: 10.1097/RLU.0000000000002499.

PMID:
30789399
15.

Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage.

Simopoulos DN, Sisk AE Jr, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, Marks LS.

BJU Int. 2019 Jan 29. doi: 10.1111/bju.14691. [Epub ahead of print]

PMID:
30694605
16.

Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.

Eur Urol. 2019 Jul;76(1):18-23. doi: 10.1016/j.eururo.2018.12.036. Epub 2019 Jan 24.

PMID:
30685078
17.

Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.

Tsai WK, Zettlitz KA, Tavaré R, Kobayashi N, Reiter RE, Wu AM.

Theranostics. 2018 Nov 12;8(21):5903-5914. doi: 10.7150/thno.27679. eCollection 2018.

18.

Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial.

Sadun TY, Reiter RE.

Eur Urol. 2019 Apr;75(4):591-592. doi: 10.1016/j.eururo.2018.12.023. Epub 2018 Dec 24. No abstract available.

PMID:
30591355
19.

PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.

J Urol. 2019 Jan;201(1):91-97. doi: 10.1016/j.juro.2018.08.043.

PMID:
30577397
20.

Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.

Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker ER, Lu DSK, Reiter RE.

Eur Urol. 2019 May;75(5):712-720. doi: 10.1016/j.eururo.2018.11.031. Epub 2018 Dec 1.

PMID:
30509763
21.

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M.

EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z.

22.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

23.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

PMID:
30326032
24.

Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.

Zhang M, Kobayashi N, Zettlitz KA, Kono EA, Yamashiro JM, Tsai WK, Jiang ZK, Tran CP, Wang C, Guan J, Wu AM, Reiter RE.

Clin Cancer Res. 2019 Jan 1;25(1):188-200. doi: 10.1158/1078-0432.CCR-18-1382. Epub 2018 Oct 9.

PMID:
30301826
25.

Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT.

Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J.

Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55. doi: 10.1016/j.clgc.2018.09.003. Epub 2018 Sep 7. No abstract available.

PMID:
30293922
26.

Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation.

Mirak SA, Shakeri S, Bajgiran AM, Felker ER, Sung KH, Asvadi NH, Khoshnoodi P, Markovic D, Ponzini D, Ahuja P, Sisk A, Reiter RE, Lu D, Raman SS.

J Urol. 2019 Mar;201(3):496-502. doi: 10.1016/j.juro.2018.09.054.

PMID:
30273608
27.

PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.

J Urol. 2019 Jan;201(1):91-97. doi: 10.1016/j.juro.2018.08.043.

PMID:
30142318
28.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
29.

Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center.

Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE.

Urol Oncol. 2018 Sep;36(9):401.e19-401.e25. doi: 10.1016/j.urolonc.2018.06.006. Epub 2018 Jul 29.

PMID:
30064933
30.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

31.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
32.

3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.

Asvadi NH, Afshari Mirak S, Mohammadian Bajgiran A, Khoshnoodi P, Wibulpolprasert P, Margolis D, Sisk A, Reiter RE, Raman SS.

Abdom Radiol (NY). 2018 Nov;43(11):3117-3124. doi: 10.1007/s00261-018-1598-9.

PMID:
29725743
33.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

34.

Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.

Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, Donahue TR, Reiter RE, Wu AM.

J Nucl Med. 2018 Sep;59(9):1398-1405. doi: 10.2967/jnumed.117.207332. Epub 2018 Mar 30.

35.

Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP.

J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30.

PMID:
29602819
36.

A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.

Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE.

J Urol. 2018 Sep;200(3):564-572. doi: 10.1016/j.juro.2018.03.004. Epub 2018 Mar 7.

PMID:
29524506
37.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

38.

Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate.

Nagarajan MB, Raman SS, Lo P, Lin WC, Khoshnoodi P, Sayre JW, Ramakrishna B, Ahuja P, Huang J, Margolis DJA, Lu DSK, Reiter RE, Goldin JG, Brown MS, Enzmann DR.

Abdom Radiol (NY). 2018 Sep;43(9):2487-2496. doi: 10.1007/s00261-018-1495-2.

PMID:
29460041
39.

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.

Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018.

40.

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.

J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.

41.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

42.

Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.

Tan N, Shen L, Khoshnoodi P, Alcalá HE, Yu W, Hsu W, Reiter RE, Lu DY, Raman SS.

J Urol. 2018 May;199(5):1218-1223. doi: 10.1016/j.juro.2017.10.042. Epub 2017 Nov 8.

PMID:
29128577
43.

Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study.

Kishan AU, Cheng EM, Schmidt E, Saigal C, Reiter RE, Kupelian PA, Steinberg ML, King CR.

JCO Clin Cancer Inform. 2017 Nov;1:1-6. doi: 10.1200/CCI.17.00046.

44.

Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.

Donin NM, Reiter RE.

J Nucl Med. 2018 Feb;59(2):177-182. doi: 10.2967/jnumed.117.191874. Epub 2017 Oct 6. Review.

45.

Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.

Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, Marks LS, Natarajan S.

J Urol. 2018 Feb;199(2):453-458. doi: 10.1016/j.juro.2017.08.085. Epub 2017 Aug 19.

46.

Multi-parametric magnetic resonance imaging as a management decision tool.

Johnson DC, Reiter RE.

Transl Androl Urol. 2017 Jun;6(3):472-482. doi: 10.21037/tau.2017.05.22. Review.

47.

Anatomic and Molecular Imaging in Prostate Cancer.

Miller ET, Salmasi A, Reiter RE.

Cold Spring Harb Perspect Med. 2018 Mar 1;8(3). pii: a030619. doi: 10.1101/cshperspect.a030619. Review.

PMID:
28710256
48.

Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.

Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU.

Urology. 2017 Sep;107:171-177. doi: 10.1016/j.urology.2017.05.028. Epub 2017 May 25.

PMID:
28552819
49.

Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma.

Jamshidi N, Margolis DJ, Raman S, Huang J, Reiter RE, Kuo MD.

Radiology. 2017 Jul;284(1):109-119. doi: 10.1148/radiol.2017162827. Epub 2017 Apr 28.

50.

Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

Hegde JV, Margolis DJ, Wang PC, Reiter RE, Huang J, Steinberg ML, Kamrava M.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):241-248. doi: 10.1038/pcan.2016.75. Epub 2017 Jan 31.

PMID:
28139757

Supplemental Content

Loading ...
Support Center